The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Machine learning modeling of protein-intrinsic features predicts tractability of targeted protein degradation
Open accessPreprint — published as 10.1016/j.gpb.2022.11.008 · Paper page
Abstract
Targeted protein degradation (TPD) has rapidly emerged as a therapeutic modality to eliminate previously undruggable proteins by repurposing the cell’s endogenous protein degradation machinery. However, the susceptibility of proteins for targeting by TPD approaches, termed “degradability”, is largely unknown. Recent systematic studies to map the degradable kinome have shown differences in degradation between kinases with similar drug-target engagement, suggesting yet unknown factors influencing degradability. We therefore developed a machine learning model, MAPD (Model-based Analysis of Protein Degradability), to predict degradability from protein features that encompass post-translational modifications, protein stability, protein expression and protein-protein interactions. MAPD shows accurate performance in predicting kinases that are degradable by TPD compounds (auPRC=0.759) and is likely generalizable to independent non-kinase proteins. We found five features with statistical significance to achieve optimal prediction, with ubiquitination potential being the most predictive. By structural modeling, we found that E2-accessible ubiquitination sites, but not lysine residues in general, are particularly associated with kinase degradability. Finally, we extended MAPD predictions to the entire proteome to find 964 disease-causing proteins, including 278 cancer genes, that may be tractable to TPD drug development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Highly accurate protein structure prediction with AlphaFold
Jumper, J., Evans, R., Pritzel, A., Green, T., Figurnov, M., Ronneberger, O., Tunyasuvunakool, K., Bates, R., Žídek, A., Potapenko, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03819-2 · Cited by 43,764
Global quantification of mammalian gene expression control
Schwanhäusser, B., Busse, D., Li, N., Dittmar, G., Schuchhardt, J., Wolf, J., Chen, W., & Selbach, M. (2011) · Nature · doi:10.1038/nature10098 · Cited by 6,566
Flagged first, then by citations
Research works printed but not linked: 109
- 10.1146/annurev.genet.30.1.405 · DOI
- 10.1152/physrev.00027.2001 · DOI
- 10.1016/S0092-8674(03)01074-2 · DOI
- 10.1016/S0092-8674(00)80929-0 · DOI
- 10.1073/pnas.141230798 · DOI · Paper page
- 2008, Targeted intracellular protein degradation induced by a small molecule: En route to chemical proteomics, Bioorganic & Medicinal Chemistry Letters, 18, 5904, 10.1016/j.bmcl.2008.07.114 · DOI · Paper page
- 10.1073/pnas.89.4.1249 · DOI
- 2017, Small-Molecule Modulation of Protein Homeostasis, Chemical Reviews, 117, 11269, 10.1021/acs.chemrev.7b00077 · DOI
- 2020, Prospecting for molecular glues, Nature chemical biology, 16, 1157, 10.1038/s41589-020-0620-z · DOI · Paper page
- 10.1016/j.cell.2019.11.031 · DOI · Paper page
- 2019, PROteolysis TArgeting Chimeras (PROTACs) — Past, present and future, Drug Discovery Today: Technologies, 31, 15, 10.1016/j.ddtec.2019.01.002 · DOI
- 10.1016/j.chembiol.2015.05.009 · DOI · Paper page
- 10.1126/science.aab1433 · DOI · Paper page
- 10.1038/nature16979 · DOI · Paper page
- 10.1038/nchembio.2329 · DOI · Paper page
- 2018, Plasticity in binding confers selectivity in ligand-induced protein degradation, Nature Chemical Biology, 14, 706, 10.1038/s41589-018-0055-y · DOI · Paper page
- 2018, The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study, Cell Chem Biol, 25, 67, 10.1016/j.chembiol.2017.09.009 · DOI · Paper page
- 2018, Targeted protein degradation and the enzymology of degraders, Curr. Opin. Chem. Biol, 44, 47, 10.1016/j.cbpa.2018.05.004 · DOI · Paper page
- 10.1016/j.chembiol.2021.04.011 · DOI
- 10.1038/s41573-021-00199-0 · DOI · Paper page
- 10.1016/j.pharmthera.2012.07.004 · DOI · Paper page
- 10.1016/S1286-4579(02)01645-3 · DOI
- 10.1073/pnas.91.9.4082 · DOI · Paper page
- 10.1097/00001622-200011000-00009 · DOI
- 10.1126/science.1177319 · DOI · Paper page
- 10.1126/science.1244851 · DOI · Paper page
- 10.1126/science.1244917 · DOI · Paper page
- 2014, Structure of the human Cereblon–DDB1–lenalidomide complex reveals basis for responsiveness to thalidomide analogs, Nature Structural & Molecular Biology, 21, 803, 10.1038/nsmb.2874 · DOI · Paper page
- 2019, Disordered region of cereblon is required for efficient degradation by proteolysis-targeting chimera, Sci. Rep, 9, 19654, 10.1038/s41598-019-56177-5 · DOI
- 2020, Novel immunomodulatory drugs and neo-substrates, Biomark Res, 8, 2, 10.1186/s40364-020-0182-y · DOI · Paper page
- 10.1126/science.1249543 · DOI
- Sievers, Q. L. et al. Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN. Science 362, (2018). · DOI · Paper page
- 10.1038/nature13527 · DOI · Paper page
- 2021, PROTAC-DB: an online database of PROTACs, Nucleic Acids Res, 49, D1381, 10.1093/nar/gkaa807 · DOI · Paper page
- 10.1073/pnas.1521738113 · DOI · Paper page
- 2020, First-in-human phase I study of ARV-110, an androgen receptor (AR) PROTAC degrader in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) following enzalutamide (ENZ) and/or abiraterone (ABI), Journal of Clinical Oncology, 38, 3500, 10.1200/JCO.2020.38.15_suppl.3500 · DOI · Paper page
- 2019, ARV-110: An oral androgen receptor PROTAC degrader for prostate cancer, Journal of Clinical Oncology, 37, 259, 10.1200/JCO.2019.37.7_suppl.259 · DOI
- 10.1158/1538-7445.sabcs18-p5-04-18 · DOI
- He, Y. et al. DT2216—a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas. Journal of Hematology & Oncology vol. 13 (2020). · DOI · Paper page
- 2020, Discovery of CRBN E3 Ligase Modulator CC-92480 for the Treatment of Relapsed and Refractory Multiple Myeloma, J. Med. Chem, 63, 6648, 10.1021/acs.jmedchem.9b01928 · DOI · Paper page
- 10.31525/ct1-nct03930953 · DOI
- 2021, Targeted protein degraders crowd into the clinic, Nat. Rev. Drug Discov, 20, 247, 10.1038/d41573-021-00052-4 · DOI · Paper page
- 2021, Reimagining Druggability Using Chemoproteomic Platforms, Acc. Chem. Res, 54, 1801, 10.1021/acs.accounts.1c00065 · DOI · Paper page
- 2020, Mapping the Degradable Kinome Provides a Resource for Expedited Degrader Development, Cell, 183, 1714, 10.1016/j.cell.2020.10.038 · DOI · Paper page
- 2018, A Chemoproteomic Approach to Query the Degradable Kinome Using a Multi-kinase Degrader, Cell Chem Biol, 25, 88, 10.1016/j.chembiol.2017.10.005 · DOI · Paper page
- 2018, Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead, Cell Chem Biol, 25, 78, 10.1016/j.chembiol.2017.09.010 · DOI · Paper page
- 10.1016/j.chembiol.2021.07.002 · DOI
- 10.1101/451948 · DOI
- 2019, In Silico Modeling of PROTAC-Mediated Ternary Complexes: Validation and Application, J. Chem. Inf. Model, 59, 1634, 10.1021/acs.jcim.8b00872 · DOI · Paper page
- 2020, PRosettaC: Rosetta Based Modeling of PROTAC Mediated Ternary Complexes, J. Chem. Inf. Model, 60, 4894, 10.1021/acs.jcim.0c00589 · DOI · Paper page
- 2021, Rationalizing PROTAC-Mediated Ternary Complex Formation Using Rosetta, J. Chem. Inf. Model, 61, 1368, 10.1021/acs.jcim.0c01451 · DOI · Paper page
- 10.1101/2020.07.10.197186 · DOI
- 10.1038/s41589-019-0294-6 · DOI · Paper page
- 10.1038/s41467-018-08027-7 · DOI · Paper page
- 10.1681/ASN.2006010083 · DOI · Paper page
- 2020, Proteomic analysis of degradation ubiquitin signaling by ubiquitin occupancy changes responding to 26S proteasome inhibition, Clin. Proteomics, 17, 2, 10.1186/s12014-020-9265-x · DOI
- 10.1038/35008096 · DOI
- Mészáros, B. , Kumar, M. , Gibson, T. J. , Uyar, B. & Dosztányi, Z. Degrons in cancer. Sci. Signal. 10, (2017). · DOI
- 2020, Discovery of novel resorcinol diphenyl ether-based PROTAC-like molecules as dual inhibitors and degraders of PD-L1, Eur. J. Med. Chem, 199, 112377, 10.1016/j.ejmech.2020.112377 · DOI
- 2018, Development of a Novel B-Cell Lymphoma 6 (BCL6) PROTAC To Provide Insight into Small Molecule Targeting of BCL6, ACS Chem. Biol, 13, 3131, 10.1021/acschembio.8b00698 · DOI · Paper page
- 10.1093/nar/gku1267 · DOI · Paper page
- 10.1080/02648725.2013.801232 · DOI
- Liu, H. & Motoda, H . Computational Methods of Feature Selection. (CRC Press, 2007). · DOI
- 10.1093/nar/gkx1037 · DOI · Paper page
- 10.1093/nar/gky1075 · DOI · Paper page
- 2021, Reimagining high-throughput profiling of reactive cysteines for cell-based screening of large electrophile libraries, Nat. Biotechnol, 39, 630, 10.1038/s41587-020-00778-3 · DOI · Paper page
- 10.1038/s41573-021-00245-x · DOI · Paper page
- 10.1093/nar/gkz972 · DOI · Paper page
- 2019, AnimalTFDB 3.0: a comprehensive resource for annotation and prediction of animal transcription factors, Nucleic Acids Res, 47, D33, 10.1093/nar/gky822 · DOI
- 10.1016/j.cell.2018.01.029 · DOI · Paper page
- 2020, Androgen receptor degraders overcome common resistance mechanisms developed during prostate cancer treatment, Neoplasia, 22, 111, 10.1016/j.neo.2019.12.003 · DOI
- Kim, G.-Y. et al. Chemical Degradation of Androgen Receptor (AR) Using Bicalutamide Analog-Thalidomide PROTACs. Molecules 26, (2021). · DOI
- 2019, Discovery of Highly Potent and Efficient PROTAC Degraders of Androgen Receptor (AR) by Employing Weak Binding Affinity VHL E3 Ligase Ligands, J. Med. Chem, 62, 11218, 10.1021/acs.jmedchem.9b01393 · DOI
- 10.1021/acs.jmedchem.1c00847 · DOI
- 2021, Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer, J. Clin. Oncol, 39, 1360, 10.1200/JCO.20.02272 · DOI
- 10.1158/1535-7163.MCT-20-0390 · DOI · Paper page
- 2020, GLL398, an oral selective estrogen receptor degrader (SERD), blocks tumor growth in xenograft breast cancer models, Breast Cancer Res. Treat, 180, 359, 10.1007/s10549-020-05558-w · DOI
- 10.1158/1078-0432.CCR-16-2561 · DOI
- 10.1016/j.chembiol.2012.04.008 · DOI
- 2019, A Targeted Protein Degradation Cell-Based Screening for Nanobodies Selective toward the Cellular RHOB GTP-Bound Conformation, Cell Chem Biol, 26, 1544, 10.1016/j.chembiol.2019.08.009 · DOI
- 10.1002/bip.360221211 · DOI · Paper page
- 10.1016/j.cell.2011.10.035 · DOI · Paper page
- 10.1016/j.cell.2011.09.019 · DOI
- 10.1126/science.1160462 · DOI
- 10.1126/science.1160489 · DOI · Paper page
- 10.1038/s41467-018-03106-1 · DOI
- 10.1074/mcp.RA118.000583 · DOI
- Szklarczyk, D. , et al. STRING v11: protein–protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Research vol. 47 D607–D613 (2019). · DOI · Paper page
- 10.1093/nar/gky973 · DOI · Paper page
- 10.1016/j.cell.2019.12.023 · DOI · Paper page
- 10.1016/j.cell.2020.08.036 · DOI · Paper page
- 10.1016/j.molcel.2017.06.004 · DOI · Paper page
- 10.1093/nar/gku982 · DOI
- 10.1093/bioinformatics/btw313 · DOI
- 10.1201/9780429341830-30 · DOI
- 2018, Pre-processing and Modelling using Caret Package in R, International Journal of Computer Applications, 181, 39, 10.5120/ijca2018917530 · DOI
- Robin, X. et al. pROC: an open-source package for R and S to analyze and compare ROC curves. BMC Bioinformatics vol. 12 (2011). · DOI · Paper page
- 10.1093/bioinformatics/btv153 · DOI
- 10.1186/s12859-016-1433-7 · DOI
- 10.1016/j.molcel.2020.07.001 · DOI
- 2021, RCSB Protein Data Bank: powerful new tools for exploring 3D structures of biological macromolecules for basic and applied research and education in fundamental biology, biomedicine, biotechnology, bioengineering and energy sciences, Nucleic Acids Res, 49, D437, 10.1093/nar/gkaa1038 · DOI · Paper page
- 10.1093/nar/gky427 · DOI
- 10.1093/nar/gkt1144 · DOI
- 10.1158/0008-5472.CAN-15-3190 · DOI
- 10.1093/bioinformatics/btl461 · DOI
- 10.1038/nsb1097-796 · DOI
- 10.1038/s41592-020-0848-2 · DOI · Paper page
- 10.1093/bioinformatics/bty355 · DOI · Paper page
- 10.1074/jbc.M102060200 · DOI
Metadata
- Authors
- Zhang, W., Roy Burman, S. S., Chen, J., Donovan, K. A., Cao, Y., Zhang, B., Zeng, Z., Zhang, Y., Li, D., Fischer, E. S., Tokheim, C., & Liu, X. S.
- Affiliations
- Harvard University (US)
- Sichuan University (CN)
- Corresponding author
- Fischer, Eric S.
- Tokheim, Collin
- Liu, X. Shirley
- ORCID
- Venue
- Genomics Proteomics & Bioinformatics
- Publisher
- openRxiv
- Published
- 2021-09-29
- Volume
- 20
- Issue
- 5
- Pages
- 882-898
- ISSN
- 1672-0229 (ISSN-L)
- PMC
- PMC10025769
- OpenAlex
- W4310760182
- Cited by
- 51
- References
- 2
- Citations by year
- 2026: 15 · 2025: 10 · 2024: 16 · 2023: 4 · 2022: 6
- FWCI
- 2.92
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Genomics Proteomics & Bioinformatics (publishedVersion, cc-by-nc-nd)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Digital Commons-TMC (Texas Medical Center) (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Cancer Research Institute
- Breast Cancer Research Foundation (BCRF-19-100)
- Damon Runyon Cancer Research Foundation (DRQ-04-20)
- Astellas Pharma US
- Harvard Medical School
- Dana-Farber Cancer Institute
- Deutsches Krebsforschungszentrum (CRI 3442)
- Mark Foundation For Cancer Research (19-001-ELA)
- Istituto Superiore di Sanità
- National Institutes of Health
- National Cancer Institute (R01CA214608, R01CA218278)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Machine Learning in Bioinformatics
- Keywords
- targeted protein degradation, kinases, undruggable proteins, cancer genes
- MeSH terms
- Machine Learning, Lysine, Proteome, Ubiquitination, Proteolysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review